IGHE and asthma: In patients with severe asthma and perennial allergies, anti-IgE (omalizumab) may reduce exacerbation rates [118,137]: Patients with symptoms of allergic rhinitis are more likely to benefit from omalizumab with a substantial reduction in symptoms of rhinitis, as well as those of asthma [138].